InVitae Corp (NVTA) 2024年CSR报告「NYSE」.pdf

《InVitae Corp (NVTA) 2024年CSR报告「NYSE」.pdf》由会员分享，可在线阅读，更多相关《InVitae Corp (NVTA) 2024年CSR报告「NYSE」.pdf（85页珍藏版）》请在三个皮匠报告上搜索。

1、From genetics,health2024 Environmental,Social&Governance(ESG)ReportTable of contentsTo experience all of the features of this report,download it as a PDF.Introduction.3From our CEO.4About Invitae.5Our ESG approach.92023 ESG highlights.14Healthcare for all.17Improving outcomes and scientific advancem

2、ents .20AI at Invitae.21Expanding access to underserved populations .25Driving access through advocacy and public policy.27Social responsibility.32Our people and culture.34Quality and product safety.46Supply chain management.50Governance and responsible business practices .60Corporate governance.62R

3、isk management and business continuity.63Business ethics and compliance.65Privacy and data security .69Environmental sustainability.52Management and employee engagement.54Energy and GHG management .56Waste and water management.58Appendix.72ESG data table.73United Nations Sustainable Development Goal

4、s(SDGs).75Sustainability Accounting Standards Board(SASB).78Task Force on Climate-Related Financial Disclosures(TCFD)82Forward-looking statements.85 2 Invitae 2024 ESG reportIntroductionHealthcare for allSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixIntrod

5、uctionGenetic information can transform the way medicine is practiced,making what once seemed impossible possible.We aim to help people make decisions about their health through the power of genetics.In this sectionFrom our CEO.4About Invitae.5Our ESG approach.92023 ESG highlights.14 3 Invitae 2024

6、ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportFrom our CEOIn 2023,Invitae continued on a transformative journey that reshaped our organization and redefined our commitment to purpose-driven pro

7、gress.We continued our focus on streamlining our operations,optimizing patient impact and nurturing sustainable growth.This journey necessitated tough decisions.It also reignited our collective purpose and dedication to our patients.Over the past decade,our purpose-led strategy in genetics-based hea

8、lthcare has guided our dedicated team and partners to help improve health outcomes and transform the lives of over 4.6 million patients and their families.It fills me with pride to introduce Invitaes 2024 Environmental,Social and Governance(ESG)report.This report shares how we create a positive impa

9、ct,especially in the lives of our patients.It also highlights our environmental initiatives,social responsibility commitments and governance efforts.We firmly believe that our success is tied to our sustainability strategy and rooted in our distinctive culturea culture committed to making healthcare

10、 better for everyone.As we reflect on 2023,I am pleased to highlight some of our notable achievements:Expanding patient access and partnerships:We concentrated our efforts on expanded access to genetic testing,resulting in policies,programs and guidelines that now qualify more patients and their fam

11、ilies to receive testing.Since inception,we have proudly served over 4.6 million patients and,in 2023,expanded our partnerships in rare diseases and data to advance drug discovery.Advancing genetic insights:We strengthened our industry-leading variant classification,Invitae Generation capabilities,t

12、hrough cutting-edge technologies such as machine learning and functional modeling.These tools empower us to continue to improve the accuracy of our genetic insights.With optimism for the futurefrom genetics,health.Ken D.Knightpresident and CEO Standard of quality:We obtained market authorization fro

13、m the United States(US)Food and Drug Administration(FDA)for one of our hereditary germline cancer panels,a testament to our stringent standards and product quality.Our hereditary cancer panels give patients and their families vital information for informed healthcare decisions.Environmental sustaina

14、bility:We made progress managing Scope 1 and 2 greenhouse gas emissions,and we assessed the relevance of the different Scope 3 categories in our value chain.We also adopted a board-level Environmental Policy.Environmental sustainability is at the core of our ESG journey.I extend my heartfelt gratitu

15、de to our exceptional team members for their dedication,hard work and focus on our patients and on supporting our greater missionbringing genetic information into mainstream medicine and creating a healthier future for all.As you delve into this report,I hope you share in my excitement for better he

16、althcare through genetic testing,for a brighter future for our planet and for the well-being of its people.Together,we will continue to profoundly impact healthcare and the world around us.To our valued patients,clinicians,team members,investors and stakeholders,4 Invitae 2024 ESG reportHealthcare f

17、or allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixAbout InvitaeInvitaes founding principlesInvitae was founded on four principles that seek to improve access,health equity,quality and affordability of healthcare,including efforts to provide g

18、enetic testing for all who can benefit.This foundation depends on partnerships and collaborations among patients,providers,academic institutions,researchers and the medical community.Headquarters:San Francisco,CA1,509 global employees&expertsInvitae is a leading medical genetics company trusted by m

19、illions of patients and their providers to deliver timely genetic information using digital technology.We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families.Invitaes genetics experts apply a rigorous approach to data and research.T

20、he ability to identify those at risk for disease,detect and diagnose the onset earlier,use that information to guide preventive measures or targeted treatment and monitor the success of that treatment will become the standard of care for individuals throughout multiple stages of their lives.5 Health

21、care for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportDriving down the cost of obtaining genetic information will increase its personal and clinical utility.1Individuals have a fundamental right to own and control the

22、ir personal information.2Clinicians are critical partners in using genetic information to make better healthcare decisions.3Genetic information is more valuable when shared within the academic and medical communities.4Invitaes mission is to bring comprehensive genetic information into mainstream med

23、icine to improve healthcare for billions of people.O U R M I S S I O N 6 Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportImpact of genetic testingInvitae at a glance Invitae has a 10-year track record of p

24、ioneering genetic testing for the benefit of individuals and scientific research.*4.6 million+patients served 3.0 million+million patients trust Invitae to responsibly share their information to enable advanced research 2 million+unique gene variants interpreted 1.7 million+gene variants submitted t

25、o ClinVar to improve the science of genetics200+1,029,000 billable units$487 million unaudited revenues4,575+available gene tests 360+available panel tests 1,509 employees and experts62%Female 38%Male research publications authored and collaborated on 80%+of National Cancer Institute(NCI)centers acr

26、oss the US have used Invitaes hereditary cancer genetic testing10-year+track record of pioneering genetic testing to benefit individuals and scientific research*All numbers listed are as of 12/31/23 unless otherwise noted 7 Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabil

27、ityGovernance,trust and transparencyAppendixInvitae 2024 ESG report“Our unwavering commitment is to ensure that all patients,regardless of their background,gain access to the vital genetic information that shapes their future health and impacts their families.”Dr.Michael Korn chief medical officer a

28、t InvitaeFrom genetics,health Delivering the promise of precision medicine Identifying new ways to prevent diseaseInforming cures to eradicate diseaseImproving therapies and treatment optionsDeveloping better tests for diagnosing diseasePrecision medicineWhat is it,and what is Invitaes role?Precisio

29、n medicine(or personalized medicine)is an emerging approach that uses individuals genetic profiles to guide decisions related to their medical management.Precision medicine aims to provide a more precise approach to disease prevention,diagnosis and treatment.Were focused on shaping the future of hea

30、lthcare,making personalized care the standard for all.The promise of precision medicine is supported by large volumes of patient data becoming accessible to researchers.In the long term,this can only happen if patients and communities trust those who collect,curate and aggregate their data.Each pati

31、ent engagement may generate different data and insights.As a company,we make it possible for patients to choose whether to share their data for research,allowing us to pool their data with other patient data to create valuable data sets.These data sets can enable new insights into how genetics impac

32、t health and disease and can potentially lead to transformative outcomes.8 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixOur ESG approachOur ESG approach reflects our passion for reaching more patients,s

33、upporting clinicians and advancing genetics.We developed the following core tenets to represent the principles that direct our actions,guide our decision-making across all levels of the organization and form the foundation of our sustainability efforts.Healthcare for allWe want to bring comprehensiv

34、e genetic information into mainstream medicine to improve healthcare for people worldwide.Environmental stewardshipWe work to minimize our environmental impact and reduce our emissions footprint.Social responsibilityWe implement programs that instill ethical practices and increase diversity,equity a

35、nd inclusion among employees,patients,suppliers and partners throughout our value chain.Governance,trust and transparencyWe ensure our governance structure and policies promote ethical,transparent and accountable business practices to drive corporate performance and value.9 Invitae 2024 ESG reportHe

36、althcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixESG oversightOur Board and management oversight drives accountability for a range of ESG areas designed to maximize our impacts,drive better business performance and create long-term

37、 value for our stakeholders.Invitaes Board of Directors(Board)is committed to strengthening oversight and integration of ESG within our long-term strategy and risk management practices.While the entire Board engages in corporate ESG matters,the Nominating and Governance Committee(NGC),per its charte

38、r,has oversight responsibility for our company-wide corporate social responsibility(CSR)and ESG strategy,initiatives and policies,including climate-related issues.Board oversightOur senior executive leadership team(Management team)oversees ESG performance and risk management and reports to the NGC.T

39、he chief sustainability officer(CSO)is appointed by the chief executive officer(CEO)and reports to the chief operating officer.The CSO oversees our day-to-day sustainability program and advances our multi-year effort to improve ESG capabilities in all areas of our business,including climate matters.

40、The CSO provides the Management team and Board liaison progress updates at least quarterly,and the full Board receives ESG updates on a semi-annual basis.Due to structural changes within Invitae in 2023,responsibilities shared by the Management-level ESG steering committee have shifted to the CSO,wh

41、o drives Invitaes sustainability program and keeps leadership apprised of updates,challenges and key decisions.We increased ESG reporting to the Board in 2023 to align with our new structure.Management oversightWe introduce ESG to all new hires during orientation and build an understanding of how ES

42、G informs decision-making across all levels of Invitae.We instill a culture of empowerment and communicate expected action on ESG factors with all employees.Employee education 10 Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixI

43、nvitae 2024 ESG reportMateriality assessmentIn 2023,we conducted our inaugural ESG materiality assessment to better understand the core topics most relevant to our long-term financial sustainability.Invitae,along with a third-party ESG expert,narrowed hundreds of ESG factors across our four key ESG

44、tenets down to the 20 most relevant factors.We then assessed the importance of each ESG factor to both external and internal stakeholders,referencing key ESG frameworks and standards,ESG rating agencies,industry norms,existing and emerging regulations,peer best practices and stakeholder surveys.The

45、materiality assessment identified eight factors as the most important to external and internal stakeholders:Access and affordability Quality and product safety Data security Patient privacy Labor practices and employee well-being Employee engagement,training and development Business ethics Risk mana

46、gement(including climate risk)and business continuityThe findings of this assessment will guide our reporting and inform our strategic decisions,ensuring that we address material ESG issues effectively and align our actions with the expectations of our stakeholders.In our ongoing commitment to ESG,w

47、e maintain transparency by communicating our performance and impacts throughout this report.“At Invitae,our commitment to our patients goes beyond the status quo.Its about more than just execution;its about pioneering change and embracing transformation in our operations.We believe in leading by exa

48、mple,showing that patient care is not just about the services we provide but also about how we adapt and evolve to meet the needs of those we serve,sustainably.This dedication ensures that every step we take is a step toward a healthier,more informed world.”David Sholehvar,MD chief operating officer

49、 at Invitae 11 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixStakeholder engagementWe understand that engaging with our internal and external stakeholders is critical for long-term business success.We pr

50、oactively engage them in continuous dialogue regarding our business and sustainability efforts through open discussion,collaboration and transparent disclosure.We apply stakeholders valued perspectives to inform,prioritize and continually improve our ESG strategy and advance our social and environme

51、ntal initiatives.Our stakeholdersWays we engageKey ESG topics addressedPatients and healthcare professionals Collaborative workshops to shape product strategy and development Informative programs on topics such as disease,oncology and data aggregation Data Use Committee to address data sharing,priva

52、cy and health research Patient advocacy organizations to address testing access,clinician practice policies and lab oversight legislation Fact sheets and email/phone outreach on policy-anchored initiatives Patient network with access to deep genetic research Town halls on the importance of genetic t

53、esting access and pharmacogenomic testing impacts Underserved patient populations Access to genetic testing and studies Testing affordability How genetic data empowers patients to improve their health and well-beingEmployees Digital communications,all-company town halls,team meetings and team member

54、 surveys Executive leadership emails and videos Volunteerism and community support Professional development and training Corporate culture and labor practices Compensation and benefits Employee engagement and retention Training and development Diversity,equity and inclusion Health and well-beingInve

55、stors Quarterly earnings calls Email,calls and in-person meetings Participation in conferences and forums Annual stockholders meetings Financial performance and business model Board composition and governance Environmental strategy Diversity,equity and inclusionGovernment agencies and policymakers D

56、irect engagement with government officials Lobbying and advocacy Congressional briefings Formal comments and requests for information Healthcare regulations and policy issues Patient advocacy Genetic testing regulations,privacy considerations and patentsSuppliers Direct engagement with our suppliers

57、 Supplier code of conduct Supplier questionnaires and assessments Circular lifecycle and waste reduction efforts upstream and downstream Ethical and transparent business operations Treatment of workers and workers rights Environmental stewardship and carbon emissions reduction efforts 12 Invitae 202

58、4 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixAbout this reportInvitaes annual ESG report reflects our commitment to giving investors and other stakeholders a transparent and holistic view of our ESG approach,perfo

59、rmance and progress.This report covers the progress of our ESG program during the 2023 fiscal year(FY2023),with data and metrics reflecting the period from January 1,2023,through December 31,2023,unless otherwise noted.In some instances,we include information on initiatives continued into 2024,which

60、 weve noted.We also provide additional sources for convenience.To ensure we address the ESG factors most relevant to our business,we align our disclosures with Sustainability Accounting Standards Board(SASB)standards(now part of the International Financial Reporting Standards IFRS Foundation)related

61、 to health care delivery and relevant topics from healthcare biotechnology and pharmaceuticals.We have identified four United Nations Sustainable Development Goals(SDGs)that offer the greatest opportunity for impact given their relevance to our business activities and key priority areas.Finally,this

62、 report also includes a summary of climate-related disclosures aligned to the Task Force on Climate-Related Financial Disclosures(TCFD)recommendations,which provides an overview of our governance,strategy,risk management and key metrics related to climate change.Please refer to the Appendix at the e

63、nd of this report for more information.“At Invitae,sustainability isnt just a function;its woven into the very fabric of our DNA.Weve embraced sustainability and ESG as catalysts for transformative change.Throughout this journey,our unwavering commitment to our patients and customers remains paramou

64、nt,ensuring that our actions positively impact on healthcare,the environment and society.”Erik Kaiser chief sustainability officer at InvitaeEnsure healthy lives and promote well-being for all at all agesReduce inequality within and among countriesEnsure sustainable consumption and production patter

65、nAchieve gender equality and empower women and girls 13 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixSocial responsibilityHealthcare for all2023 ESG highlightsInvitaes purpose and values guide our aim t

66、o provide healthcare for all,uphold our social responsibilities,exercise environmental stewardship and govern with trust and transparency throughout our business.These highlights reflect our progress during FY2023.Invested in state-of-the-art,artificial intelligence-based sophisticated computational

67、 methods to better inform clinical variant classification in genetic testing results in underrepresented populations Leveraged Invitaes vast genetic testing experience to highlight the need for improved methods to deliver definitive results at a higher rate for underrepresented populations Obtained

68、FDA market authorization for one of our hereditary germline cancer panels,a testament to our stringent standards and product quality;hereditary cancer panels empower patients and their families with vital information for informed healthcare decisions Advocated for expanded access to genetic testing,

69、resulting in policies and guidelines that now qualify more patients and their families for genetic testing Launched a company-wide belonging survey and identified key wins related to the inclusive ecosystem within our organization Strong relationships within teams:Employees reported effective workin

70、g relationships and feeling accepted and valued by their direct teammates An open and inclusive environment:Rather than brushing diversity away,Invitaens largely embrace it and accept one another for their differences Employee favorability by identity factors:We examined the survey data to assess si

71、gnificant disparities in employee favorability by race,ethnicity and gender and none were identified 77%of our Board and 44%of our Management team reflect diversity by race,ethnicity and gender 100%of our direct suppliers adopted our Supplier Code of Conduct or provided internal requirements or code

72、s equal to or exceeding our requirements representing$116.5 million$4.47 million of our direct spending is with certified minority or women-owned suppliers 14 Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG repo

73、rtGovernance,trust and transparencyEnvironmental stewardship2023 ESG highlights(continued)Developed an Environmental Policy,which was adopted by the Board of Directors,to outline our commitments and approach to environmental stewardship Submitted our first customer data platform(CDP)questionnaire Me

74、asured and disclosed our Scope 1 and Scope 2 greenhouse gas emissions for the third year and completed Scope 3 materiality screening to identify the most relevant Scope 3 categories Expanded our Code of Business Conduct and Ethics to include sustainability,human rights and DEI considerations Conduct

75、ed third-party due diligence to detect and mitigate corruption risks in our value chain Developed generative AI processes and procedures to address the use of external or third-party generative AI products,tools and services 15 Healthcare for allIntroductionSocial responsibilityEnvironmental sustain

76、abilityGovernance,trust and transparencyAppendixInvitae 2024 ESG report“Healthcare is steadily transforming,and at its heart lies the power of genetics.Its not just about treating diseases any more;its about understanding individual genetic profiles to prevent illness and enhance lives.The future is

77、 personalized,predictive and remarkably promising.”K E N K N I G H T P R E S I D E N T A N D C E O 16 Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportHealthcare for allWe provide affordable testing,data se

78、rvices,integrated health information and digital solutions to shape genomic medicine and support patients through all stages of life.Genomic information allows healthcare to rely less on trial and error and more on fact-based analysis of biology and medical risks.2023 highlightsPublished studies bas

79、ed on Invitaes genetic testing data,analysis and insights to highlight the need for improved methods to deliver definitive results at a higher rate for underrepresented populationsInvested in developing state-of-the-art machine learning(artificial intelligence-based)methods that can better inform cl

80、inical variant classification in genetic testing results in underrepresented populationsWorked with patient advocacy groups to prepare the latest updates on clinical management information for certain genetic disordersOur work contributes to the following SDGs:In this sectionImproving outcomes and s

81、cientific advancements .20AI at Invitae.21Expanding access to underserved populations .25Driving access through advocacy and public policy.2717Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportInvitae aims t

82、o broaden access to genomic information through ethical data sharing,research studies,expanded guidelines and affordability.18 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG report2 0 23

83、S P OT L I G H TReceived first-of-its-kind authorization from the FDA for a version of our Common Hereditary Cancers Panel;we have been active in the regulatory community in helping shape regulatory pathways that support both patient access and test qualityReleased the second Data Use Transparency a

84、nd Impact Report describing how Invitae protects the privacy of our patients while using patient-shared data to drive scientific advancementsSubmitted information more than 500,000 variants into the public NIH ClinVar database,which brings our total submission as the top submitter to more than 1.7 m

85、illion variantsWeve actively championed the successful transformation of outdated medical guidelines that govern an individuals ability to access genetic testing and expanded testing pathways for family members 19 Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGoverna

86、nce,trust and transparencyAppendixInvitae 2024 ESG reportImproving outcomes and scientific advancements“Invitae has always vigorously pursued scientific research to advance medical genetics for the public good.In addition to generating evidence to improve clinical guidelines for genetic testing and

87、publishing more than 200 scientific articles,Invitae has sustained its unwavering commitment since its inception to data-sharing.Our efforts push the science forward in clinical laboratory genetics and aid clinicians,researchers and genetics laboratories around the world.”Swaroop Aradhya,PhD chief o

88、f global medical affairs at InvitaePatients who opt to share their data for research through Invitae contribute to scientific advancements by furthering our understanding and application of medical genetics.In 2023,Invitae worked on several research projects and publications that emphasized expandin

89、g access to better genetic information for everyone,including underserved populations.Our data formed the basis of research published in top research and medical journals,including:In September 2023,Invitae received first-of-its-kind authorization from the FDA for a version of our Common Hereditary

90、Cancers Panel.This represents the first broad panel to gain market authorization that is used to identify germline variants associated with hereditary cancer.7 3416963Invitae-led publicationscollaborative publications with research institutionspublications related to advancing healthcare for allpubl

91、ications related to diversity,equity and inclusion in geneticsabstracts at 21 conferences 20 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixAI at InvitaeUsing AI to increase accessAs part of Invitaes busi

92、ness strategy and commitment to make genetic testing equitable across global populations,we invested in developing state-of-the-art machine learning(artificial intelligence-based)methods to better inform clinical variant classification in genetic testing results in underrepresented populations.Invit

93、ae has demonstrated leadership in clinical variant classification over the last decade.We continue to further advance this science and reduce uncertainties so that more patients can receive conclusive results.Invitaes innovative and state-of-the-art machine learning methods had already produced reli

94、able evidence for variant classification and contributed to reducing uncertainty in results for more than 300,000 individuals,particularly for historically underrepresented populations.Publication of second Data Use Transparency and Impact ReportSince the founding of Invitae more than decade ago,our

95、 commitment to get data right has been based on establishing core principles regarding data ownership and use.We embedded those principles in Invitaes corporate DNA,culture and activities.Patient-directed data drives positive healthcare change.To build on our commitment to data transparency,we publi

96、shed our second industry-leading Invitae data use transparency and impact report in December 2023.The report details how we obtain consent and de-identify(anonymize)patient data.We then use those data to help advance precision medicine research,promote patient advocacy and enhance patient outcomes,i

97、mproving healthcare for individuals and society.In 2023 we also revised our informed consent forms in response to new privacy laws enacted in several US states.Generative artificial intelligence(AI)policyInvitae established a standard operating procedure and policy in 2023 to address the use of exte

98、rnal or third-party generative AI products,tools and services and ensure compliance with applicable laws,regulations and policies governing Invitaes products,services and employee use.Invitae data use transparency and impact report:2022 data 21 Invitae 2024 ESG reportHealthcare for allIntroductionSo

99、cial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixLandmark study shows Invitaes sophisticated computational methods better inform clinical variant classification in genetic testing results for diverse populationsA recent study published in JAMA Network Open eval

100、uated data from more than 1.6 million people who underwent multi-gene panel testing for hereditary diseases.The study delved into the prevalence and characteristics of uncertain DNA variants and methods to reclassify them for definitive results.Uncertainty in genetic testing is frustrating for patie

101、nts,clinicians and labs,because results are not actionable.A notable finding in this study was that the prevalence of uncertain variants differs based on race,ethnicity and ancestry(REA),as well as by age group and clinical area.For example,Ashkenazi Jewish and White individuals had the lowest numbe

102、r of observed uncertain variants per individual,while Pacific Islander and Asian individuals had the highest.Therefore,expansion of the data used for variant classification to populations across the globe is needed to reduce uncertain results for historically underrepresented populations and make ge

103、netic testing equitable.Find more information here.22 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixBroadening access through affordabilityInvitae works to broaden patient access to genetic testing so in

104、dividuals can collaborate more effectively with their providers to shape personalized,informed care with the goal of improving outcomes.Over the last decade,weve offered a growing number of affordable options to remove cost barriers and make genetic healthcare more available.Transparent pricing,insu

105、rance coverage and lower costs With Invitae,patients can access affordable and flexible billing options through a simplified process.Our pricing practices are transparent,and we offer patient pricing on request.Invitae is proud to be in-network with all national payers,covering more than 300 million

106、 patients in the United States,which typically helps limit out-of-pocket costs.Through the Invitae Billing Assurance Program,our dedicated billing specialists work with each patient to get a comprehensive view of their individual situation and help identify cost-effective and affordable payment opti

107、ons.We provide patients with proactive information about our broad insurance coverage,payment options and billing cost estimates.Our team is also on-hand to provide patients with necessary information on insurance coverage and claims processing.In addition,we accept Medicare and Medicaid.Patient ass

108、istance programsWe may offer testing at little or no charge if the patient qualifies for our patient assistance program whereby United States-based patients who meet certain income criteria may be eligible for financial help.“Putting patients first and expanding access to genetic information are the

109、 cornerstones of revolutionizing mainstream medicine.Our mission goes beyond innovation;we ensure every individual can benefit from the groundbreaking possibilities in genetic medicine.”Robert Guigley chief commercial officer at Invitae 23 Healthcare for allIntroductionSocial responsibilityEnvironme

110、ntal sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportFamily variant testingWe strive to facilitate a better understanding of a patients results and their associated implications for family members,recognizing the impact of genetics on family health.All blood relatives o

111、f patients found to have a pathogenic(disease-causing)or likely pathogenic variant on an Invitae diagnostic or proactive test are eligible for family variant testing(FVT).Our family variant testing reports on the variant(s)identified in the original family member,as well as any other pathogenic vari

112、ant(s)found in the full gene.Family variant testing is part of our commitment to lowering barriers to genetic testing.We believe that all people should have access to their genetic information so they can make informed health decisions,such as early action to prevent the onset of disease,more freque

113、nt or earlier screenings or alternate reproductive choices.By offering FVT,we enable more people to access crucial genetic information at no costa significant initiative for Invitae.Variants of uncertain significance(VUS)testingIn some cases,Invitae may offer family testing to help resolve a variant

114、 of uncertain significance(VUS).When an Invitae panels test results arent definitive and further testing may clarify the relationship between the variant and the patients genetic condition,we offer follow-up testing at no additional charge to family members.Sponsored testing programs remove barriers

115、 to patient access To help improve access to genetic testing,we offer sponsored programs at no charge to eligible patients.These testing programs are primarily sponsored and paid for by biopharma companies with targeted treatments for diseases caused by specific genes.Sponsored programs aim to remov

116、e barriers to genetic testing and speed diagnosis.These programs may also help bring patients closer to better clinical management of their diseases,as well as raise awareness of clinical trials and research opportunities.In 2023,Invitae continued to partner with biopharma organizations to offer spo

117、nsored testing programs to:improve patient access to genetic testing help speed diagnosis raise awareness of clinical trials and research opportunitiesBy the numbers:Invitae-offered sponsored testing25 biopharma partners23 distinct sponsored testing programs 24 Invitae 2024 ESG reportHealthcare for

118、allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixExpanding access to underserved populations Were working to ensure that genetic testing improves the care and health outcomes of historically underserved populations.Were building digital workflo

119、w solutions to help scale genetic testing in the community healthcare setting where the vast majority of underserved populations have access.We also actively reach out to physicians and the public to target populations with specific genes and diseases of concern that the scientific community has not

120、 historically addressed.Weve made progress,but data from specific underserved populations are still scarce due to a historical lack of inclusion and focus in the medical literature.We regularly publish research studies alongside leading institutions on the impact of genetics on patients from underse

121、rved populations,illustrating its clinical utility and underscoring the importance of universal genetic testing to help improve health outcomes for all patients.Reinforcing equitable processes for patients is of the utmost importance,and we continue to actively voice our opinions about regulations t

122、hrough our Policy team.This includes raising our concerns regarding the FDAs proposed laboratory developed test(LDT)rule and its potential to restrict access to underserved communities.See additional detail in section 2.4 Driving access through patient advocacy and public policy.Many case studies de

123、monstrate Invitaes strong commitment to making genetic testing more equitable through investing in medical and scientific communities,conducting research and ensuring genetic testings position at the forefront of scientific advancement.“Expanding access to genetic testing for traditionally underserv

124、ed populations has been core to our values since day one.This is evident from our family variant testing,sponsored testing,and other programs that allow access to genetic testing for many patients who would have been unable to participate in these initiatives through traditional routes.”Britt Johnso

125、n,PhD,FACMG clinical molecular and biochemical geneticist at Invitae 25 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixClinical benefits of implementing universal hereditary cancer testing in rural breast

126、 cancer patientsIn collaboration with The Outer Banks Hospital(TOBH)in North Carolina,from 2019 to 2022,Invitae conducted a study that showcased how to implement universal hereditary cancer genetic testing for rural breast cancer patients.The results revealed significant enhancements to patient care

127、,including alterations in treatment plans and surgical decisions.Genetic testing proved particularly beneficial for rural populations who face disparities in care accessibility,because it helps optimize clinical practices,reduce unnecessary surgical procedures and minimize unnecessary healthcare res

128、ource utilization.Find more information here.Broadening genetic testing of all prostate cancer patients,particularly Black menInvitaes research,featured in European Urology Oncology,highlights that restrictive genetic testing criteria overlook a considerable number of prostate cancer patients,partic

129、ularly Black men with potentially actionable inherited variants linked to more aggressive disease.The results suggest expanding guidelines by recommending universal germline genetic testing for all prostate cancer patients.This shift has the potential to redefine medical care standards and reduce he

130、althcare disparities(especially for historically underrepresented groups);broadening access to precision therapies,clinical trial treatments and enhanced screening.Find more information here.Implementing hereditary cancer testing and digital tools for underserved and tribal communitiesInvitae collab

131、orated with the New Mexico Cancer Center(NMCC)to develop a playbook for implementing hereditary cancer testing and digital tools(such as the GIA chatbot)in community settings for underserved and tribal communities.In September 2023,we presented the playbook at the National Cancer Care Alliance(NCCA)

132、conference to share recommendations on how to scale these best practices in a community setting.Our collaboration with NMCC improved the Navajo Nations access to genetic testing,more accurate individual and family health records and education on the importance of genetics in healthcare.26 Invitae 20

133、24 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixDriving access through advocacy and public policyAs thought leaders in the genomics industry,Invitae uses alliances,research and advocacy to push healthcare forward an

134、d improve the rules and policies that limit access to genetic testing and data.We are committed to strong relationships with patient insights networks(PINs).As we work to expand access to information that helps people with genetic disorders,we collaborate directly with patient advocacy groups to ens

135、ure their perspectives are included in our work.We continue to work with the Electronic Medical Records and Genomics(eMERGE)Network.This NIH-funded effort supports genomic discovery and genomic medicine implementation research that includes underrepresented populations.Advancing policies and guideli

136、nes on genetic testingMedical associations and governmental bodies establish guidelines,create educational campaigns and outline policies that impact who can receive genetic testing and when,if that testing is covered by insurance and the type of test.We champion efforts to advance the policies and

137、guidelines that remove barriers to accessing genetic healthcare and improving outcomes.Our research studies on the clinical utility of genetic testing in health outcomes have contributed(along with our policy and advocacy efforts)to updating professional practice guidelines for the testing and care

138、of patients.These guidelines direct physician behaviors,including cancer prevention and treatment standards,as well as insurance and payer coverage of testing protocols.Through this multifaceted research approach,we focus on ensuring that patients have more access to genetic information,that screeni

139、ng and testing are more affordable and that protocols support the best life outcomes for people managing risks,conditions and diseases.Invitae sponsors the Heart of Genetic Counseling AwardInvitae joined the National Society of Genetic Counselors(NSGC)in presenting the Heart of Genetic Counseling Aw

140、ard,which honors excellence in genetic counseling and patient care as recognized by patients.The nominations included patient stories that highlight the significant clinical and personal impact their genetic counselor had on their lives and the lives of their families.In research presentations at th

141、e NSGC conference,Invitae also highlighted the importance of genetics-informed patient care,demonstrated how using digital tools can increase hereditary cancer screening access and discussed other topics related to the field of medical genomics.Find more information here.27 Invitae 2024 ESG reportHe

142、althcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixChampioning public policy to expand genetics utility within healthcareWe have built strong relationships and created alliances with organizations including the American Cancer Societ

143、y,Healthy African American Families,the Personalized Medicine Coalition,California Clinical Laboratory Association and rare disease patient groups to collaborate with stakeholders and amplify our voices.We also continue to focus on federal and California state legislative efforts.Invitae does not ha

144、ve a political action committee.We rely on diplomacy and high-quality policy proposals to support expanding access to genetic testing.Remaining diligent in the changing environment is a priority for Invitae.In 2023,our Policy team continued to take actions in alignment with Invitaes mission to incre

145、ase access to high quality healthcare for all.Access to genetic testing intersects with many important issues,so the Policy team engaged in approximately 128 meetings and 41 comment opportunities.Public policy efforts by the numbersspent on contributions to campaigns,politicians,parties or committee

146、s,or to influence ballot measures$0spent on retaining lobbyists for consultative and legislative support$433,000spent on engaging with trade associations and patient advocacy groups$360,000meetings between Invitae representatives and congressional and California state offices to discuss legislative

147、priorities120+comment letters submitted to the state of California,United States and international governments40+“As we forge ahead,our commitment to shaping a healthcare landscape that welcomes genetics into standard care remains unwavering.This journey is not just integral to our growth strategy;m

148、ore important,it is a vital conduit for clinicians and patients to access genetic insights and elevate healthcare standards for all.”Chantelle Schenning,PhD,MHA head of public policy at Invitae 28 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityG

149、overnance,trust and transparencyAppendixMedi-Cal coverage of pharmacogenomic testing in CaliforniaInvitae was the lead sponsor for a first-of-its-kind policy in California to add Medi-Cal coverage of pharmacogenomic testing.Pharmacogenomics is the science of how an individuals genes impact the way t

150、he body processes medications.There are differences in medication response across race,ethnicity and sex.In support of Assembly Bill 425,designed to increase access to genetic testing to make medication decisions,Invitaes Policy team conducted nearly 80 meetings with California legislators,staffers,

151、agencies and government officials;convened a sign-on letter;and submitted six letters of support.Invitaes Policy team effectively worked with legislators and patient advocates to get this legislation enacted into law.Effective July 1,2024,more than 14 million Californians will have access to a previ

152、ously unattainable,potentially lifesaving test.Additional state-level effortsInvitae participated in several other efforts to improve access and equity in individual states.We engaged in a collaborative workgroup of supporters for the American Cancer Society Cancer Action Networks(ACS CAN)effort to

153、increase access to genetic testing throughout the US with their state coverage mandates.This advocacy led to 14 states enacting legislation requiring coverage for genetic testing.At the state level,we also supported Assembly Bill 85 in California,which addresses social determinants of health data,an

154、d Senate Bill 570,which maintains reproductive choice for patients seeking non-invasive prenatal screening.Through Invitaes advocacy,we helped provide education on issues facing Californiansand propose solutions to fix them.29 Healthcare for allIntroductionSocial responsibilityEnvironmental sustaina

155、bilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportFederal effortsInvitaes Policy team was also active on a federal level,engaging more than 50 meetings and submitting more than 20 letters and public comments across issues.Two initiatives Invitae helped lead were the reintroductio

156、ns of the 2022 H.R.5989 Precision Medicine Answers for Kids Today Act and the 2022 H.R.6875 Right Drug Dose Now Act.These bills will increase access to diagnostic and pharmacogenomic testing for children suspected of having a rare condition.To promote the Right Act,we hosted a congressional briefing

157、 in March 2023 and met with Capitol Hill staff.We also promoted access and equity by writing comment letters that address racial and ethnic disparities in healthcare,enhancing care for dual-eligible individuals,increasing patient access to at-home medical technologies and improving technology and wo

158、rkforce capacity to increase patient access.We also supported legislation that would remove barriers to telehealth services(S 2016/HR 4189),improve access to hereditary cancer testing(S 765/HR 1526),increase coverage of genetic counseling services(S 2323/HR 3876)and improve coverage of diagnostic te

159、sts for cancer patients(S 642/HR 1780).Engagement with industry associationsOur research helped us advocate alongside clinicians and advocacy organizations to request changes to the NCCN Clinical Practice Guidelines In Oncology(NCCN Guidelines)to increase genetic testing eligibility.This would make

160、it an option for more individuals and their families facing hereditary breast,ovarian,pancreatic,uterine and colorectal cancer and fluorouracil(5FU)toxicity.Through research,we were able to demonstrate that a significant number of colorectal cancer patients with actionable variants have been missed

161、under previous genetic testing guidelines.As a result,we were able to bring about changes to the NCCN Guidelines for genetic testing access in colorectal cancer,and we are optimistic about their application to future guidelines.Working with other associations,Invitae advocated for the development of

162、 a quality measure to encourage germline genetic testing in individuals with a personal history of cancer.The goal is to align the quality measures,and the reimbursement models attached to them,with the new NCCN Guidelines.Invitae also submitted a letter to the American Urological Association(AUA)Pr

163、actice Guidelines Committee with a recommendation that clinicians should offer all patients with prostate cancer the opportunity to receive comprehensive germline genetic testing.30 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust

164、 and transparencyAppendixOpposing policies and regulations limiting patient accessWhile most of our advocacy includes supporting policies and regulations that would increase access,we do not shy away from expressing opposition to policies and regulations that would decrease patient access.Invitae ha

165、s been a longtime opponent of patents for naturally occurring genetic material and other products of nature.When the Patent Eligibility Restoration Act(S 2140)was reintroduced,our team jumped into action to share why the legislation,if passed,would invariably hinder patient access and drive up the c

166、osts of tests.Another major effort was sharing our experience with the medical device regulatory review pathway to inform the FDAs rulemaking on laboratory-developed tests(LDTs).We collaborated with other industry stakeholders to submit thoughtful responses about the impacts of the proposed rule.If

167、this rule is adopted,it will lead to market consolidation and reduced testing choices that will affect all patients.People with rare diseases,in particular,stand to bear the brunt if their access to diagnostic testing services significantly diminishes.Protection of patient health dataData privacy an

168、d sharing are important to promote access and equity in healthcare.Patients lack of trust in how healthcare providers will handle their sensitive health data can be a barrier to healthcare access.Invitae believes that patients own their data and control how that data is used and shared.We adhere to

169、this belief through internal company policies and via policy advocacy on behalf of patients.On the patient privacy side,we commented extensively about protecting reproductive data,ensuring appropriate identity proofing when data are requested,and promoting general privacy and protection of patient h

170、ealth data.To find more about our commitment to privacy and data transparency,see the Invitae Data Use Transparency and Impact Report:2022 Data(latest reporting year).On the sharing side,we offered insights on how the Ciitizen platform enables patients to more easily view their longitudinal data and

171、 to share that data to advance research into the development of treatments for complex medical conditions,including rare diseases.In addition to leveraging technology to reduce burdens imposed by prior authorizationas we explained in our comments to the Centers for Medicare and Medicaid Serviceswe a

172、lso educated legislators extensively on the utility of real-world evidence and testing-generated data that may enable better clinical trials.In two letters to the FDA,we recommended using real-world data to support innovative clinical trial designs,including those using external data sets.With our c

173、ontinuous advocacy for access,affordability,technology,data protection and responsible sharing,Invitae continues to help shape thoughts on improving healthcare to truly serve everyone.We are committed to the privacy and security of all protected health information(PHI)we create,receive,use,disclose

174、and transmit.31 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixSocial responsibilityOur commitment to our people and communities is intrinsically linked to our mission to improve healthcare.Were dedicated

175、 to fostering a culture of diversity,equity and inclusion to positively impact our people and business.2023 highlightsHired a new DEI leader Launched a company-wide belonging survey administered by an external consultantOur work contributes to the following SDGs:In this sectionOur people and culture

176、.34Quality and product safety.46Supply chain management.5032Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportInvitae is responsible for ensuring its people thrive through a diverse,equitable,inclusive and s

177、upportive company culture.33 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportStrategic realignmentIn 2023,Invitae reshaped our organization to focus on streamlining our operations,op

178、timizing our impact in genetics-based healthcare and nurturing sustainable growth.This journey necessitated tough decisions such as the discontinuation of certain workstreams,but it ignited a collective sense of purpose.Our people and cultureOur team is driven to make a difference for patients.We ai

179、m to be high-functioning and collaborative,well-equipped to attract,develop and retain diverse talent while driving culture,engagement and change management in support of business objectives.“At Invitae,our people are our greatest asset,and their success is our success.Our commitment is to ensure th

180、at our employees have the support,resources and opportunities they need to thrive in their roles.Together,we build a stronger,more empowered workforce that drives our mission forward.”Desarie French chief talent officer at Invitae2023Total headcount 1,509Total headcount(US)1,489Total headcount(non-U

181、S)20 34 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixSupporting our purpose-driven cultureOur Employee Experience and Diversity,Equity and Inclusion(DEI)team works closely to build a collaborative,suppo

182、rtive and inclusive culture through engagement initiatives.We host employee forums to bring employees together with senior management to learn the current status of our business operations,build a collective purpose-driven culture and discuss areas of employee concern.Teammates throughout the compan

183、y,including our management and extended leadership teams,attend these bi-weekly sessions.The consistency and transparency of this process help ensure employees feel seen,heard and connected to senior company leaders.Employee engagement As part of our commitment to data-driven decision-making,we cond

184、uct a monthly pulse survey that asks our teammates three questions:1)How do you feel about the companys direction?2)Whats going well?3)Whats not going well?Weve asked these questions consistently for several years so we can quickly identify trends as they emerge and inform management decision-making

185、.We also continued our team surveys to gauge how employees feel about the effectiveness of their teams and the identification of helpers and blockers to cross-functional success.Our leadership teams get feedback regarding manager effectiveness and annual updates about the health of our culture to su

186、pport continuous improvement.Our surveys allow employees to escalate their comments to our People&Culture committee,which will address concerns and follow up.We distribute a weekly newsletter to all teammates to call their attention to important company announcements,details on new product offerings

187、,benefits updates,reminders about upcoming events,links to resources and team recognition.Were committed to drive our mission and advance the transformative healthcare that is core to Invitae-led by our energized and passionate team of professionals.35 Invitae 2024 ESG reportHealthcare for allIntrod

188、uctionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixBenefits and wellnessWe aim to create a culture where our employees thrive and innovate.We encourage an environment where theyre empowered to speak up,try new things and make decisions that push us forwar

189、d.Health and well-beingWe offer mental health benefits to support employee well-being,including including confidential behavioral health screenings,decision guidance,case management assistance and telehealth care for behavioral health.We provide resources from our employee assistance program(EAP)to

190、support our employees and their families health and well-being.Our wellness strategy also offers personal health activities such as guided meditation sessions.Compensation and benefitsWe offer a competitive total rewards package,which includes base compensation,incentive compensation,equity,access t

191、o a 401(k)plan(with a partial match),an employee stock purchase plan and a broad range of other benefits,such as:health,dental,vision,short-and long-term disability,critical illness and basic life insurance coverage flexible paid time off and holiday pay fully paid public transit commute expenses fo

192、r on-site employees We offer family leave benefits,including parental leave for new parents.Our health vendor provides fertility and adoption benefits for our US population and most global employees.Invitae has an employer-sponsored genetic testing program,which gives employees and their covered dep

193、endents access to Invitae genetic testing at no cost.For employees who do not work on-site in our laboratories,we consider ourselves a remote-first company and provide flexible,hybrid working arrangements with the option to work remotely,in-office or through a mix of the two options.36 Invitae 2024

194、ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixDiversity,equity and inclusionAddressing inequality is essential to our mission.Were committed to ensuring equitable representation,engagement and advancement of all empl

195、oyees,especially those from historically underserved and disenfranchised communities.Our DEI mission and strategyOur commitment to diversity,equity and inclusion at Invitae starts with building a culture that fosters belonging for all our employees,particularly those with historically marginalized i

196、dentities and lived experiences.We define diversity as the collective ways we differ from each other,and we strive to create a fulfilling and rewarding workplace that welcomes those differences.Invitaens are connected by a culture grounded in clear feedback and communication,care for the growth of o

197、ur employees and a deep sense of community that connects us all.We lead by example.Through our collective impact,we foster greater inclusion and belonging.As we build a diverse workforce,we aim to cultivate a place where we all belong.Our DEI mission is to engage,develop and retain talent by fosteri

198、ng community,providing education and support and advancing inclusive research and health equity globally.We have a dedicated team focused on driving this effort.Our strategy is to weave rich DEI programs,tools and resources into the fabric of Invitae.Objectivity,data integrity and accountability dri

199、ve these initiatives and inspire more representative,fair and empathetic decision-making.Belonging at InvitaeDiversity,equity and inclusion culminate in feeling connected to each other and being our full selves 37 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmenta

200、l sustainabilityGovernance,trust and transparencyAppendixDiversityAll the ways in which people differEquityEqual treatment,opportunity and advancement for all peopleInclusionOrganizational efforts and practices that ensure value and acceptance of all individuals,identities and ideas Oversight Were p

201、roud of our leadership diversity and work to ensure a fair and equitable workplace for people of all backgrounds,ethnicities and races.Our chief talent officer(CTO)and head of DEI lead our efforts in driving,growing and championing Invitaes DEI strategy,supported by our Management team.By creating D

202、EI programs,they serve as trusted,inspiring leaders who ensure a sense of belonging for all Invitae colleagues.Belonging surveyIn 2023,our DEI team launched a company-wide anonymous belonging survey designed to understand employee perceptions around diversity,equity and inclusion at Invitae.We surve

203、yed 849 Invitae employees across seven dimensions(validation,psychological safety,healing and reparation,justice,access to decision-making,opportunity and feedback)and three pillars(engage effectively across difference,foster trust across different backgrounds and empower different perspectives and

204、beliefs).Invitae demonstrated key wins in two major areas according to the belonging survey.Across both quantitative survey data and qualitative comments,employees spoke positively of their relationships with their most direct and immediate colleagues.By and large,employees reported effective workin

205、g relationships and feeling valued and accepted by their direct teammates.The second win demonstrated strength in fostering an open and inclusive workplace.Employees at Invitae,specifically from historically underrepresented and marginalized communities,spoke of a work environment that welcomes dive

206、rsity and differences in several ways.Rather than brushing diversity away,Invitaens largely embrace it and accept one another for their differences.3 pillars7 dimensionsfoster trust across different backgroundsengage effectively across differenceempower different perspectives and beliefsvalidationps

207、ychological safetyhealing and reparationaccess to decision-makingjusticeopportunityfeedback 38 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixWhite 55.3%Asian 21.4%Black or African American 6.7%Two or mor

208、e races 4.5%Hispanic or Latino 9.6%Native Hawaiian or Pacific Islander 0.5%American Indian or Alaska Native 0.1%Do not wish to answer 0.5%Not known 1.3%Employee diversity metrics Non-binary and gender-nonconforming(GNC)individuals are not currently identifiable by our self-reporting payroll system,w

209、here we derived these metrics.Diversity among all employees2023Gender:employeesGender:management teamRacial/ethnic diversity(US only)Male 38.0%Female 62.0%Male 77.0%Female 23.0%Management team racial/ethnic diversity 11.0%39 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityE

210、nvironmental sustainabilityGovernance,trust and transparencyAppendixEqual Employment Opportunity Commission EEO-1 data DEI transparency is important to us at all levels of the organization.Invitae reports EEO-1 annual data to the federal government and makes it publicly available on our website as r

211、equired by law.Diversity recruitment strategyBuilding a diverse workforce starts with new hires.Were investing in technology and updating our processes to support data-driven,inclusive practices and create consistent,people-oriented candidate experiences that reduce recruitment bias.We use a third-p

212、arty artificial intelligence(AI)tool to write job descriptions with neutral language for candidates across all backgrounds and genders.Total denominator does not include those who did not self-identify race/ethnicity.New hiresTurnover Rates2023202351.1%Men29.6%Total turnover rate(all employees)48.9%

213、Women39.6%White(US only)10.5%Involuntary turnover rate60.4%Racial/ethnic diversity(US only)19.1%Voluntary turnover rate 40 Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportDEI awareness trainingOur talent m

214、anagement program incorporates DEI training to create a workplace where team members feel safe to stretch,rebuild and evolve professionally and personally.We train our employees on managing unconscious bias.This foundational program addresses workplace bias and provides tools to engage in equitable

215、decision-making and build an inclusive culture.In 2023,we expanded training for Invitae leaders to better understand how to mitigate bias in their day-to-day work and interactions.This training established the foundations of defining and understanding bias,then explored practical and tactical ways t

216、o actively mitigate both conscious and unconscious bias with their teams and peers.Invitaes Talent Acquisition team,as evangelists of our equity and inclusion strategy,also participate in training to improve inclusive hiring practices and collaboration with the business.“At Invitae,we foster a cultu

217、re of belonging,celebrating diversity in all forms.Our mission is to engage,develop and retain talent while championing inclusive research and global health equity,weaving DEI into the very fabric of our organization.”Cherise Bernard,PhD head of diversity,equity and inclusion at InvitaeEmployee reso

218、urce groupsInvitae believes that employee engagement directly connects to purpose,and through our employee resource groups(ERGs),we foster connections and meaningful work relationships.Since 2020,Invitae has hosted ERGs for employees to create stronger bonds based on shared identities and life exper

219、iences of historically underrepresented,underserved and disenfranchised individuals.Highlights of our ERG program in 2023 include:launched a task force,led by ERG and DEI leaders,to craft the Inclusive Language Guide for the organization leaned into creating meaningful and impactful experiences arou

220、nd cultural and social moments for the organization led conversations and learning experiences around relevant topics such as mental health,ability and racial and gender impact on health equity41Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGov

221、ernance,trust and transparencyAppendixOur ERGs aim to serve three primary purposes:Invitasians exists to celebrate the cultural differences and similarities within the Asian and Pacific Islander diaspora.BlackGenX exists to support and uplift Invitae employees who identify as members of the African

222、diaspora.Differently Abledfocuses on creating a supportive and inclusive environment for Invitaens of all abilities.Genetic Counseling at Invitae exists to cultivate a community for those interested or involved in the field of genetic counseling.LatinX supports individuals who identify as Latinx by

223、openly discussing topics integral to the Latinx identity.Rainbow Connection provides a safe space for LGBTQIA+individuals and allies.Veterans-in-Genetics serves Invitae employees called into service or with family members who serve in the military.Women-in-Healthcare supports and empowers womens gro

224、wth,both personally and professionally.Peer Soul Support Teamfocuses on mental munitylearningservice123 42 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixLearning and developmentOur corporate mission anch

225、ors our talent development strategyour“why.”Namely,we strive to develop our workforce to live our leadership principles,which equips our team to execute our mission.All employees enroll in mandatory and optional education to continue their personal career development,and we regularly monitor and aud

226、it the required training compliance.Leadership programInvitaes leadership principles are foundational to our learning practices and capture what weve found to be critical skills and observable behaviors that best help our team deliver results.They link all talent processes:hiring,developing talent,d

227、ifferentiating performance,assessing potential,building a leadership pipeline,maintaining a strong leadership bench and and implementing succession planning.Leadership principlesAware Calm is contagious Courage Curiosity Improve&grow Ownership Passion Swift execution Team VulnerableMore than 250 new

228、 leaders participated in Leads 101,acquiring deeper understanding and competence in critical skills and behaviors outlined in our leadership principles.Invitaes senior leadership facilitates the program twice annually,offering community-building and peer learning and welcoming new members of Invitae

229、s extended Leadership team.We conducted the following monthly workshops on developing leadership and management skills:Situational Leadership,Coaching Habits,Giving and Receiving Feedback,Emotional Intelligence,Influencing without Authority,Conflict Resolution and Team Dynamics and Compassion Fatigu

230、e.Experiential learning 70%Stretch assignmentsOn-the-job and project-based learning Managing relationships 20%CoachingMentoringCommunities of practice to share knowledge and expertise Formal development 10%Courses and workshopsLearning Strategy 43 Healthcare for allIntroductionSocial responsibilityE

231、nvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportLearning and development metrics for FY2023Performance management In keeping with our commitment to creating a differentiated,equitable workplace,we developed a performance management system unique to our cult

232、ure.Everyone,including the Management team,can give and receive continuous feedback regardless of seniority,experience or level.Our performance management framework includes quarterly reviews with performance assessments and professional development discussions with managers.Leads receive additional

233、 learning opportunities to develop their management and leadership skills.949 LinkedIn training hours 13,592enterprise training hours 16,246learning video hours “At Invitae,we empower our workforce to embody our mission and leadership principles through continuous learning and development.Our commit

234、ment to mandatory and optional education ensures our teams growth,fostering a culture of excellence.”Nicole Francis-Mason head of talent management and attraction at Invitae 44 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and

235、transparencyAppendixEmployee health and safety(EH&S)All employees are responsible for maintaining a safe workplace.Our training aims to ensure employees follow our protocols,rules,policies and practices.We also require them to report accidents,injuries and unsafe equipment,practices and conditions i

236、n accordance with our Code of Conduct and environment,health and safety(EH&S)policies.Environment,health and safety training We continue to expand our employee health and safety initiatives through comprehensive and up-to-date training.Our training programs include general EH&S awareness for non-lab

237、 groups.We also provide lab-specific EH&S training for lab personnel and contractors.All employees are required to complete general EH&S awareness training on hiring and annually.This training incorporates our Emergency Action Policy,which outlines what to do in an emergency.In 2023,we required lab

238、personnel and contractors to take a course of training on many subjects,including:injury and illness prevention emergency action and fire prevention personal protective equipment ergonomics emergency contact biosafety and bloodborne pathogens(exposure control)chemical hygiene and hazard communicatio

239、n hazardous and medical(biohazardous)waste management infectious disease(including COVID-19)In 2023,95%of employees completed EH&S training.Oversight and compliance Our Quality Group controls standard operating procedures(SOPs).The EH&S,Quality,Facilities and Laboratory directors and personnel revie

240、w and approve the policies annually and as needed.Our health and safety program includes consent forms,employee safety reports,incident investigations and injury logs.We are an International Organization for Standardization(ISO)15189-accredited,College of American Pathologists(CAP)-accredited and Cl

241、inical Laboratory Improvement Amendments(CLIA)-certified clinical diagnostic laboratory.As a leader in advanced medical genetics,we aim to comply with all local,state and federal regulations.We conduct quarterly EH&S quality and safety inspections at our primary lab in San Francisco,California.In 20

242、23,we had two Occupational Safety and Health Administration(OSHA)recordable injuries and zero Environmental Protection Agency(EPA)reportable incidents,with a Total Recordable Incident Rate(TRIR)of 0.128.45 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustai

243、nabilityGovernance,trust and transparencyAppendixQuality and product safetyWe have policies and standard operating procedures to manage health and safety.We promote,provide training on,and ensure that employees follow the protocols and practices in accordance with our Code of Conduct and health and

244、safety policies.By going above and beyond,we ensure that every test and every result will be a step towards advancing patient care and trust in the precision of medical genetics.For us,quality is a promise to our patients,our partners and the communities we serve,where every patient deserves to get

245、the right test and the right results at the right time.Leadership and oversight Cross-functional leaders support our quality management system(QMS)with oversight from the Global Quality Assurance team,which reports to the chief operating officer.The chief medical officer is a key sponsor of the QMS.

246、Medical Affairs and Operations leadership are responsible for the standard of care provided by Invitae clinical laboratories and works with leadership to ensure appropriate controls.Quality management review(QMR)is the periodic systematic process by which our Leadership team reviews key performance

247、indicators that demonstrate the health of our QMS.Quality Assurance(QA)typically facilitates the review in partnership with key stakeholders,including executive leadership,Operations,Commercial,Medical Affairs and Regulatory Affairs.We incorporate the results of the management review into action pla

248、ns,which include goals,objectives and effectiveness checks.Various mechanisms assist in documenting the action plans at Invitae,including those used for objectives and key results(OKRs)and individual quality improvement plans(QIPs).“Each of our laboratories meets or exceeds local and international s

249、tandards,embodying our commitment to unparalleled quality.Our accreditations are proof of our dedication to maintaining the highest standards in laboratory excellence.”Patty Cerulle head of site quality assurance at Invitae 46 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilit

250、yEnvironmental sustainabilityGovernance,trust and transparencyAppendixQuality complianceWe built our QMS on the principles of ISO 9001,15189 and applicable elements of ISO 13485,plus specific country standards such as CLIA and FDA regulations.Local regulatory agencies license each facility and adher

251、e to relevant country-specific requirements.We gain accreditation through appropriate bodies.We comply with country-specific requirements and standards applicable to the geography of our facilities and the country where we provide services.In our US clinical laboratory facilities,we meet or exceed I

252、SO,CLIA and College of American Pathologists(CAP)standards and implement required elements set by the FDA.Assessments validate the trust in our capabilities.Our quality systems exceed the minimum required standards for clinical laboratory testing by also incorporating elements of quality system requ

253、irements for manufacturers.For a complete list of our licenses and certifications,please visit the Licensing section of our website.Leaders in laboratory accreditation:Beyond CAP guidelines,CLIA and New York state(NYS)regulationsInvitae laboratories earned accreditation by the International Organiza

254、tion for Standardization(ISO)Our San Francisco and Metropark labs earned the distinction of ISO 15189 accreditation for Clinical Laboratories.Embracing the ISO 15189 standard underpins confidence in the quality of medical laboratories through a process that verifies our integrity,impartiality and co

255、mpetence.Invitae is one of 50 clinical labs that achieved both CLIA and ISO 15189 certificationsWere in the company of other world-class institutions such as the Mayo Clinic,St.Jude Childrens Research Hospital and Associated Regional and University Pathologists(ARUP)Laboratories.47 Healthcare for al

256、lIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportQuality control and assuranceQuality control(QC)and QA programs ensure the effectiveness of our processes.We have several levels of internal controls throughout the stages of

257、 genetic testing,such as:document controls(policies,procedures and work instructions)nonconformity management process controls(procedures and statistical process controls SPCs)material controls that dictate how we control raw materials before production use equipment controls(installation,operationa

258、l and performance qualifications,calibrations and monitoring)verification and control of materials(quality control,batch controls and lot controls)change control(validation and verification of process changes)corporate audit program training and competency program Employee training and awareness on

259、qualityOur quality training begins when employees are hired,enabling us to effectively communicate the requirements needed for each persons role.For employees performing regulated tasks within the QMS,we require training before performing duties and competency assessments within six months of the in

260、itial training assignment(and annually thereafter).All employees participate in ongoing training specific to their roles.48 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixPerformance monitoring,certificat

261、ions and auditsInvitae has a culture of continuous improvement and uses certain methods to monitor performance trends,identify improvement opportunities,implement corrective actions and monitor the effectiveness of those actions.We achieve continuous improvement through activities including:customer

262、 complaints and customer satisfaction surveys internal and external audits key performance indicator(KPI)analysis defect trends(incident response/change acceleration process/deviations)Lean Six Sigma quality management reviews Invitae has implemented core laboratory quality performance monitors and

263、reviews them every month for tracking,trending and continuous process opportunities.Areas monitored include:corrected and amended reports incidents/corrective action program sample volumes complaints audits(internal and external)document control change managementIncident reporting frameworkInvitaes

264、incident reporting framework program guides the management of nonconformities,which may impact patient care.These procedures ensure the timely identification,remediation,corrective action and communication of activities,tasks,processes,changes or system improvements generated as a result of an inves

265、tigation of a nonconformity.We require all employees to identify,document and report any incident or complaint that impacts or potentially impacts the quality of test results or harms client satisfaction.Incidents include any nonconformance involving the violation of the Health Insurance Portability

266、 and Accountability(HIPAA)or international privacy regulations.Invitae staff train in investigative techniques such as Process Failure Modes and Effects Analysis(PFMEA)and root cause analysis(RCA).Our reporting system allows us to address immediate problems and analyze data and trends over time,incl

267、uding frequency and where in the process it occurred,to identify systemic issues and root causes.We categorize each incident based on severity and follow guidelines and regulations regarding agency notification,including specific procedures outlining adverse event management and potential product re

268、calls.Invitae 2023 auditsLed to the successful renewal of all core laboratories certifications for CAP,CLIA and NYS18 external13 internal 49 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixSupply chain man

269、agementSupplier quality managementThe Supplier Quality team oversees our quality management program,ensuring a robust supply chain that operates ethically,sustainably and in line with legislation and standards.The Supplier Quality team ensures supplier quality via policies,procedures,contracts,perfo

270、rmance monitoring and problem escalation.Invitae designed its supplier quality program to meet applicable standards such as ISO 15189 and ISO 13485.In periodic management reviews,we maintain and assess selected metrics to measure the programs overall health.Our supplier qualification program incorpo

271、rates risk assessment and quality agreements with companies on our approved supplier list(ASL).In 2022,the Supplier Quality team performed a thorough,three-year review of supplier-caused quality incidents,managed internal audits and initiated corrective action as needed.We set a higher bar for our t

272、op suppliers with closer oversight,defining“critical to quality”as the suppliers that significantly impact products and services.For these critical suppliers,we identify alternatives and contingencies where possible.We developed a supplier issue resolution(SIR)procedure to address when an incident o

273、r nonconformance investigation identifies an approved supplier as the possible root cause of a quality issue.The procedure starts with a notification to Corporate Supplier Quality(CSQ)of an issue requiring investigation.CSQ reviews the internal investigation and root cause and initiates a SIR ticket

274、.Based on the suppliers issue risk ranking,CSQ issues:1.notify the supplier of the issue and then track and trend the quality issue.2.request immediate supplier correction of the quality issue.3.request that the supplier contains,investigates and identifies the root cause;corrects,prevents and verif

275、ies the effectiveness of the correction/prevention;and tracks the progress,documentation review and approval of the ticket.Invitae performs a supplier quality audit if multiple corrective action reports have been logged.Vendor compliance policiesVendors are subject to a thorough due diligence review

276、,including screening for healthcare and global sanctions,prohibited entities and countries and,if appropriate,completing a due diligence questionnaire.Our contracts have anti-corruption provisions,and applicable overseas distributor agreements contain import/export compliance language.50 Invitae 202

277、4 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixIT security and privacyOur vendor risk management program assesses potential vendors IT governance,security and data privacy policies and practices prior to the executi

278、on of contractual agreements.Our technology solutions continuously monitor a vendors risk profile and enable detailed assessments to identify data access and processing risks.Vendor risk level is determined based on data processed,vendor maturity,and potential impact to the business.All new vendors

279、are assessed for data security risks prior to approval,and all existing vendors are assessed prior to renewing a contract with Invitae.A vendor risk assessment must be completed if:the vendor will access,manage,review,analyze or store any of Invitaes data.the vendor will access Invitaes network.All

280、vendors are provided with Invitaes Supplier Code of Conduct(SCODE),which outlines our expectations for our suppliers and their subcontractors to comply with applicable laws and to operate their businesses ethically and sustainably.We also distribute our Human Rights Policy that outlines the fundamen

281、tal rights,freedoms and standards of treatment to which we believe all people are entitled.These rights include recognizing labor rights,treating all people with dignity and respect,enabling a healthy and safe work environment,promoting ethical behavior and protecting privacy.We recognize were part

282、of the communities in which we operate,and as part of our mission,we believe respect for human rights is integral to our business.Supplier diversityInvitae prioritizes the integrity and diversity of our supply chain.This year,we introduced a new supplier scorecard,actively encouraging our suppliers

283、to obtain diversity certifications.Of our direct spending,$4.5 million is with certified diverse suppliers,and we are striving to grow that figure.By the numbers:Supplier Code of Conduct100%of our direct suppliers adopted our SCODE or provided internal requirements or codes equal to or exceeding our

284、 requirements 100%of renegotiated indirect suppliers have signed our SCODE$116.5 million of spend is covered under SCODE$4.5 million of our direct spending is with certified diverse suppliers“At Invitae,we uphold ESG principles in our global supply chain,prioritizing ethical business practices and f

285、ostering strong partnerships with our vendors.Together,we continuously improve,creating a win-win scenario for all stakeholders involved.”Anna Galan head of global supply at Invitae 51 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,tr

286、ust and transparencyAppendixEnvironmental sustainabilityWe continue to integrate environmental stewardship and sustainable practices throughout our business operations and to demonstrate our commitment to stewardship where possible.2023 highlightsDeveloped and adopted an Environmental Policy that ou

287、tlines our commitments and approachSubmitted our first CDP questionnaireReinforced our dedication to operating in a responsible and sustainable manner through an Earth Month engagement campaignCompleted greenhouse gas(GHG)Scope 1 and Scope 2 inventories for the third year in a row and performed Scop

288、e 3 materiality screening to identify relevant Scope 3 categoriesImproved kit return rates through demand management and logistic strategiesOur work contributes to the following SDGs:In this sectionManagement and employee engagement.54Energy and GHG management .56Waste and water management.5852Healt

289、hcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG reportInvitae recognizes that climate change directly impacts human health and well-being,making sustainability a critical part of the companys DNA.53 Invitae 2024 ESG

290、reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixInvitae 2024 ESG report“Sustainability isnt just a goal;its a responsibility.At Invitae,we recognize the importance of minimizing environmental impact in our global operation

291、s.We are committed to making choices that ensure a brighter,more sustainable future for all.”Philip Clay vice president of integrated lab operations,global supply&workspace solution at InvitaeManagement and employee engagementOur chief sustainability officer identifies and mitigates environmental in

292、itiatives and risks,and our chief compliance officer and the Compliance committee oversee these efforts.At the Board level,the Nominating and Governance Committee provides oversight concerning the companys ESG strategy,initiatives and policies.In 2023,we developed an Environmental Policy that outlin

293、es our commitment to use our resources,influence and expertise to help protect our planet and secure a sustainable future for all.The policy will be reviewed annually,with changes approved by the NGC first and then the full Board.54 Invitae 2024 ESG reportHealthcare for allIntroductionSocial respons

294、ibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixFacility considerationsStaying true to our mission of providing for patients first and foremost,in 2023 we reduced the number of facilities we lease,own and operate.This has allowed us to focus in on locations and facilities

295、 that provide the most benefit to our testing,research and data solutions activities.This has also reduced our environmental impact due to the decrease in building maintenance as well as energy,water and waste consumption.For the facilities that we do continue to use,we incorporate environmental con

296、siderations into selection and operation.For example,several of our facilities have achieved Leadership in Energy and Environmental Design(LEED)certification or better.Were proud that our primary laboratory,in San Francisco,is LEED Gold-certified.Earth Month campaignIn April,we kicked off our Earth

297、Month campaign to encourage employees to make sustainable choices and support the environment in their homes,in their communities and at work.Together,we aim to drive a year of energy,enthusiasm and commitment to a sustainable and equitable future for our planet.Through outreach efforts and initiati

298、ng meaningful conversations,we shared insights and promoted awareness on safeguarding the planets health.Throughout the year,we rallied behind the theme“Invest In Our Planet,”highlighting the importance of dedicating our time,resources and energy to solving climate change and other environmental iss

299、ues.55 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixEnergy and GHG management We continued to examine how to minimize our environmental impact and decrease our emissions footprint in 2023.The quality an

300、d scope of our data continue to improve,allowing for a clearer picture to better inform our emissions reduction strategy.Carbon assessment Scope 1 and 2 emissionsWe collected available Scope 1 and Scope 2 data from our facilities and vehicle fleet to calculate our energy consumption and greenhouse g

301、as(GHG)emissions following the guidelines of the GHG Protocol.Our office and facility needs can change yearly,impacting our carbon footprint.Invitae closed and divested several sites,changing operations and number of locations.In 2023,we had 14 facilities in our operational control boundary,includin

302、g 11 in our GHG inventory.Inventory exclusions:three international offices,refrigeration and fire suppression,fuels combusted on-site other than natural gas(the primary fuel used by Invitae)Methodology:our GHG assessment followed The Greenhouse Gas Protocol:A Corporate Accounting and Reporting Stand

303、ard(Revised Edition)and the Greenhouse Gas Protocol:Scope 2 Guidance.MTCO2e:metric tons of carbon dioxide equivalentInvitae GHG emissions reporting Emissions in MTCO2eScope 1 emissionsStationary combustion 411Mobile sources1Fugitive sources190Total Scope 1 emissions602Scope 2 emissionsScope 2(market

304、-based)2,829Scope 2(location-based)2,681Total Scope 1 and 2(market-based)3,432Total Scope 1 and 2(location-based)3,284Energy usage in megawatt-hours(MWh)Electricity consumption8,252Fuel(stationary combustion)2,2672023 Carbon Emissions Disclosure 56 Invitae 2024 ESG reportHealthcare for allIntroducti

305、onSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixMethodologyWe calculated greenhouse gas emissions from our offices,data centers and vehicle fleet using the GHG Protocols GHG calculation methodology and the US EPAs publicly available emissions factors.US el

306、ectricity emissions factors are updated using the EPAs eGRID GHG emission factors.From 2022 to 2023,Invitaes Scope 1 and 2 emissions(location-based)decreased by 28%.This change was primarily driven by consolidating our operational footprint and reducing energy consumption within operations.In 2023,w

307、e began accounting for fugitive sources from AC equipment,which we had historically excluded from our inventory.We excluded three international laboratories due to data availability limitations.Over time,we intend to evolve our methods and improve our data collection to ensure our inventory is as co

308、mplete and accurate as possible.Energy consumptionOur total energy consumption in 2023 decreased from the previous year,a change that was primarily driven by consolidating our operational footprint throughout the reporting year.Invitae also uses colocation data centers and cloud solutions for our da

309、ta storage needs,which are both excluded from our energy footprint.We leverage cloud solutions from Amazon Web Services and Microsoft Azure,which are excluded from our operational control boundary.Both companies have publicly pledged carbon-neutral goals(Microsoft in 2030 and Amazon in 2040)and a 10

310、0%renewable energy supply by 2025.Invitae,while not permitted to provide data due to nondisclosure limitations,estimates our usage of both data centers to be less than 10%of our total carbon footprint.Scope 3 emissionsA significant portion of our total GHG footprint occurs across our entire value ch

311、ain,not just in our direct operations.In 2023,we completed a Scope 3 materiality screening to identify which of the 15 Scope 3 categories were relevant and most material to our business operations following the methods from the GHG Protocol Corporate Value Chain Reporting Standard.Results from this

312、assessment informed our overall climate strategy,including:working towards accounting for Scope 3 emissions to better understand our overall footprint identifying opportunities for emission reduction drivers prioritizing strategies to pursue stronger data quality assessing climate-related risks and

313、opportunities within our organization and value chain partners*Scope 1 and 2(location-based),see Appendix for comparison tables28%reduction in carbon emissions*year over year 57 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and

314、 transparencyAppendixWaste and water managementSupported by our Environmental Policy,we are dedicated to reducing waste generation and committed to responsible waste management.Waste managementWere committed to reducing and diverting the waste generated through our operations by recycling,composting

315、,donating and more.In 2023,we made great strides in expanding the coverage of company-wide waste data based on the data collection gaps identified by third-party analysis across our operations.Our Facilities team used these insights to enhance our data-gathering and waste diversion practices.Notably

316、,our total waste decreased from 834 tons in 2022 to 718 tons in 2023,while our non-hazardous waste diversion rate improved from 50%in 2022 to 56%in 2023.Given the plastic waste generated during our sample-to-answer process,addressing plastic waste diversion remains a top priority for our business.Pa

317、per waste is also one of our focus areas.Our Commercial team is working to decrease the number of orders placed on paper requisitions versus electronic methods.We continue to optimize Invitaes healthcare provider portal.Water usageOur facilities and offices actively submit their water usage data as

318、a continual demonstration of our commitment to sustainable business practices.By the numbers:waste and waterTotal waste Non-hazardous wasteNon-hazardous waste sent to landfillWater consumption(2023)Non-hazardous recyclingHazardous wasteNon-hazardous waste diversion rateMedical waste718 tons584 tons2

319、60 tons2,290,005 gallons324 tons106.8 tons56%27 tons 58 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixHazardous and medical waste Were committed to responsibly tracking,categorizing and disposing of haza

320、rdous and medical waste.The wastes produced by our lab operations are subject to strict regulations,and their management is covered by policies and SOPs.We treat medical waste as a separate stream,and we follow strict protocols to meet applicable rules and regulations related to its disposal.In 2023

321、,we partnered with Illumina to purchase its NovaSeq X sequencers,which will significantly improve the environmental impacts associated with our sample processing.These machines generate less chemical waste while processing more samples at once,thereby conserving energy and protecting human health an

322、d safety.We plan to operationalize these sequencers as we continuously improve our processes in 2024.See the Employee health and safety section for additional details on employee training requirements regarding hazardous and medical waste management.Specimen collection kit logisticsTo increase suppl

323、y chain efficiency and decrease the carbon footprint of our specimen collection process,we focus on two key factors in the specimen collection kit lifecycle:materials and transportation.In 2023,we increased our fulfillment efficiencies by implementing process improvements and optimizing the number o

324、f kits sent out and returned from our clients.By reducing the number of kits required by our partners with no impact to the patient experience,we can decrease materials used and waste less.This also resulted in fewer outbound shipments,reducing associated emissions.From a transportation and logistic

325、s perspective,we began consolidating multiple kits in a single package,thereby minimizing the transportation required for shipping.We are also enhancing our practices for responsible disposal of kits through ongoing recycling initiatives.In April 2023,we implemented a program to ship outbound test k

326、its via ground transit without impacting order fulfillment time to our patients and clinicians.Through this effort,about 50%of the outbound shipments were converted from air to ground transportation,lowering the level of carbon emissions associated with our shipping.59 Invitae 2024 ESG reportHealthc

327、are for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trust and transparencyAppendixGovernance,trust,transparency and responsible business practices Invitaes strategy for responsible leadership integrates resilient corporate governance,ethical business and marketing prac

328、tices and sustainable supply chain management,enhancing the interests of our stockholders and strengthening our Board and Management accountability.2023 highlights44%of our Board members identify as women,and 44%identify as an underrepresented minority22%of our Management team members identify as wo

329、men,and 11%identify as an underrepresented minority We enhanced our emergency response and resiliency practices,completing tabletop exercises related to business continuity planningThe Healthcare Compliance team conducted a third-party due diligence assessment to detect and mitigate corruption risks

330、 in our value chainOur work contributes to the following SDGs:In this sectionCorporate governance.62Risk management and business continuity.63Business ethics and compliance.65Privacy and data security .6960Healthcare for allIntroductionSocial responsibilityEnvironmental sustainabilityGovernance,trus

331、t and transparencyAppendixInvitae 2024 ESG reportInvitae believes ethical practices depend on a foundation of trust,transparency,compliance and protection for patients,customers and stakeholders 61 Invitae 2024 ESG reportHealthcare for allIntroductionSocial responsibilityEnvironmental sustainability

332、Governance,trust and transparencyAppendixInvitae 2024 ESG reportCorporate governanceGovernance and Board diversity The Board of Directors is responsible for securing the companys long-term success.Through ongoing evaluation of business needs and stakeholder interests,we shape our approach to risk ma

333、nagement,prioritize transparency,enhance supplier credibility and improve patient accessibility.The Board reflects diversity across a spectrum of experience,skills,race,ethnicity,age and gender.Recognizing that diversity generates valuable perspectives and capabilities,our Board strives to find experienced and dedicated directors with diverse backgrounds,perspectives and skills.Our Nominating and